Meranda Parascandola

Introduction  Navigating the regulatory landscape for veterinary pharmaceuticals and biologics can be complex. The U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM) and the U.S. Department of Agriculture’s Center for Veterinary Biologics (USDA CVB) oversee different aspects of veterinary product approvals. FDA CVM regulates veterinary drugs under […]

Good Manufacturing Practice (GMP) audits play a critical role in ensuring the safety, quality, and efficacy of veterinary pharmaceuticals and biologics. These audits assess compliance with regulatory requirements set forth by agencies such as the FDA’s Center for Veterinary Medicine (CVM) and the USDA’s Center for Veterinary Biologics (CVB). Non-compliance […]

The veterinary pharmaceutical industry is at a crossroads as shifting consumer behaviors, economic pressures, and evolving market demands shape the future of companion animal medicines. While the global animal health market continues to grow, stagnation in the small animal sector and a decline in canine wellness visits have presented significant […]

When it comes to developing safe, effective, and compliant animal health products, analytical processes play a critical—yet often underappreciated—role. Whether for veterinary pharmaceuticals, biologics, or medicated feeds, the rigor and precision of analytical methods are central to ensuring product quality, consistency, and regulatory approval.  At DSI, we partner with veterinary […]

The animal health industry is undergoing a significant transformation as biologicals gain traction over traditional pharmaceuticals. Driven by advancements in veterinary biotechnology, shifting market demand, and evolving regulatory frameworks, biologicals are increasingly becoming the preferred choice for disease prevention and treatment in animals. As regulatory agencies like the FDA Center […]

Introduction Bringing a new veterinary drug to market is a time-consuming and resource-intensive process. To address urgent animal health needs, the FDA’s Center for Veterinary Medicine (CVM) offers the Conditional New Animal Drug Approval (CNADA) process, which provides an expedited pathway for certain veterinary drugs. This blog explores how the […]